Atlas Trials

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Clinical trial NCT05317416 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05317416
Sponsor
Pfizer
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2022-03-25
Primary completion
2027-08-04
Enrollment
854

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.